Publications by authors named "Eric Mimbe"
Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz-Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study.
Open Forum Infect Dis
December 2023
Article Synopsis
- The NAMSAL-ANRS-12313 trial compared the efficacy of dolutegravir (DTG) versus efavirenz (EFV400) in treating HIV in low-income countries over a 96-week period, demonstrating DTG's noninferiority and continued effectiveness at 192 weeks.
- At week 192, viral suppression remained higher in participants on the DTG regimen (69%) compared to those on EFV400 (62%), with slight differences in new viral failures and serious adverse events noted between the two groups.
- Both treatment groups experienced significant weight gain, with participants on DTG/TDF/3TC gaining an average of 9.4 kg and an increase in obesity prevalence, raising concerns about
We conducted 2 independent population-based SARS-CoV-2 serosurveys in Yaoundé, Cameroon, during January 27-February 6 and April 24-May 19, 2021. Overall age-standardized SARS-CoV-2 IgG seroprevalence increased from 18.6% in the first survey to 51.
View Article and Find Full Text PDFThe extent of SARS-CoV-2 circulation in many African countries remains unclear, underlining the need for antibody sero-surveys to assess the cumulative attack rate. Here, we present the results of a cross-sectional sero-survey of a random sample of residents of a health district in Yaounde, Cameroon, conducted from October 14 to November 26, 2020. Among the 971 participants, the test-adjusted seroprevalence of anti-SARS-CoV-2 IgG antibodies was 29·2% (95% CI 24·3-34·1).
View Article and Find Full Text PDF